Bone marrow-derived cells from patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) show a defect in the expression of phosphatidylinositol-anchored membrane proteins, including the CD14 molecule.
essentially normal. The importance of the CD14 molecule in the activation of phagocytes by low LPS concentrations was confirmed by the inhibitory effect of an anti-CD14 antibody both in healthy volunteers and in PNH patients. Since these patients produce the soluble form of the CD14 molecule, these data suggest that soluble CD14 could play a role in phagocyte responses to LPS. We conclude that, in whole blood, phagocytes from PNH patients show impaired responsiveness to LPS and this phenomenon is most probably related to their defect in expression of membrane CD14.
Patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) display a lack of phosphatidylinositol-anchored proteins at the surface of bone marrow-derived cells (11, 16) . The CD14 membrane antigen, normally expressed on monocytes and to a lesser extent on granulocytes, is one of the molecules that are defective in PNH (9) . CD14 is a highaffinity receptor for bacterial lipopolysaccharide (LPS) complexed to LPS-binding protein (21) . The production of tumor necrosis factor alpha (TNF-a) by normal monocytes in response to LPS was shown to be blocked by anti-CD14 monoclonal antibodies (MAbs), suggesting that CD14 plays an important role in LPS-induced monocyte activation (19) .
However, other molecules at the surface of monocytes probably also function as LPS receptors (4, 8) .
Phagocyte activation by LPS results in the upregulation of several membrane molecules, including complement receptor Mac-1 (also called CR3 and CD11b/CD18), a molecule also involved in leukocyte adherence to vascular endothelium (12) . The increased adhesive capacity and expression of Mac-1 at the surface of LPS-stimulated granulocytes is inhibited by an anti-CD14 MAb, indicating that CD14 could also function as an LPS receptor for granulocytes (13, 20) . The role of CD14 in LPS-induced upregulation of adhesion molecules in monocytes is presently unknown. Patients  1  3  25  53  8,571  542  760  6,021  27  342  3,720  28  652  6,147  2  2  88  225  15,584  54  123  9,047  118  32  6,392  32  32  6,252   3  14  26  233  7,025  16 In vivo, the activation of circulating phagocytes by LPS probably depends both on its direct effect on these cells through specific receptors and on the induction of soluble mediators, such as cytokines and complement activation products. These different pathways of activation are operative in vitro when human whole blood is stimulated by LPS. To get insight into the role of CD14 in LPS-induced phagocyte activation, we therefore examined TNF-a and interleukin-6 (IL-6) production as well as Mac-1 expression by phagocytes from CD14-deficient PNH patients in a wholeblood model. In addition, we took advantage of these experiments to study the effect of LPS on the expression of monocyte ICAM-1, an adhesion molecule functioning as a ligand for LFA-1 (CDiia/CD18) and Mac-i (6, 12 Whole-blood stimulation. Blood obtained from PNH patients and healthy volunteers was collected in heparinized (10 U/ml) syringes. Whole blood was then incubated in polystyrene tubes (Falcon 2051; Becton Dickinson) for 2 h at 37'C with 50 ,ul of RPMI medium alone or RPMI medium containing LPS (final concentration, 1 to 1,000 ng/ml) per ml. In some experiments, whole blood was incubated with anti-CD14 blocking MAb IOM2 (20 ,ug/ml) of whole blood were suspended in phosphate-buffered saline supplemented with 0.5% bovine serum albumin and centrifuged at 2,000 rpm for 5 min. The pellets were then incubated either simultaneously with 10 ,ul of anti-Mac-1 (CDiib) or anti-ICAM-1 (CD54) MAb and 10 ,ul of anti-CD14 MAb or with fluoresceinated anti-CD14 MAb for 30 min at 4'C in the dark. In every experiment, cells were also incubated with IgG isotype-matched control antibodies. RESULTS LPS-induced production of IL-6 and TNF-a is impaired in PNH. The production of IL-6 and TNF-a in whole blood was studied after 2 h of incubation with two different concentrations of LPS (Table 1) in two independent experiments. Compared with healthy individuals, PNH patients displayed a profound defect in the secretion of both IL-6 (318 + 142 pg/ml versus 4,821 + 499 pg/ml in healthy volunteers, P < 0.001) and TNF-a (177 ± 59 pg/ml versus 8,055 ± 1,040 pg/ml in healthy volunteers, P < 0.001) at low LPS concentrations (1 ng/ml). In contrast, when whole blood from PNH patients was incubated with LPS at 100 ng/ml, the production of TNF-cx and IL-6 was similar to that in the healthy controls.
Impaired upregulation of Mac-1 and ICAM-1 molecules on CD14-deficient monocytes. The expression of the adhesion molecules Mac-1 and ICAM-1 on monocytes was measured after incubation of whole blood for 2 h in the presence and absence of LPS. As shown in Fig. 1 , the upregulation of these adhesion molecules induced by low doses of LPS (1 ng/ml) at the surface of CD14-negative monocytes was lower than that observed in healthy individuals. This difference, observed in two independent experiments involving three different donors in each group, was statistically significant (P < 0.01 for both Mac-1 and ICAM-1). Figures 2a and b display histograms of monocyte Mac-1 and ICAM-1 induction by LPS (1 ng/ml) at the surface of monocytes from patient 2 and from a representative control. When whole blood was incubated with higher LPS concentrations (100 and 1,000 ng/ml), adhesion molecule upregulation on CD14-deficient monocytes was similar to that of CD14-positive cells from healthy controls (Fig. 1) . The persistence of a normal bone marrow-derived cell population in PNH patient 3 allowed us to study the modulation of Mac-1 and ICAM-1 on CD14-positive and CD14-negative monocytes incubated in the same conditions. As shown in Fig. 3 , CD14-positive monocytes showed normal upregulation of both Mac-1 and ICAM-1 after stimulation with LPS at 1 ng/ml, whereas CD14-negative cells behaved like monocytes from PNH patients 1 and 2. In control experiments, LPS did not increase the binding of an isotype-matched control MAb. Granulocyte Mac-1 upregulation induced by low doses of LPS is impaired in PNH. Granulocytes from PNH patients are known to display, like monocytes, a defect in CD14 expression (11) . These cells were also studied for Mac-1 expression after LPS stimulation in whole blood. In patient [11]) among CD15-positive cells (a marker of granulocytes [3] ) (data not shown). The intensity of CD14 staining did not allow us to differentiate normal and abnormal cells from this patient. Therefore, only granulocytes from patients 1 and 2 were studied for LPS-induced Mac-1 upregulation. Figure 4 shows that Mac-1 upregulation at the surface of normal granulocytes was already maximal after stimulation with LPS at 1 ng/ml, whereas granulocytes from PNH patients showed only marginal upregulation by this low LPS dose. This difference, observed in two independent experiments, was statistically significant (P < 0.05). Stimulation of whole blood from PNH patients with 100 and 1,000 ng of LPS per ml induced granulocyte Mac-1 upregulation similar to that in blood from healthy controls. molecule in the activation of phagocytes by various doses of LPS, we evaluated the effects of an anti-CD14 blocking MAb on LPS-induced Mac-i upregulation and cytokine production in whole blood. We first verified that staining of phagocytes with MAb IOM2 gave the same results as MAb Leu-M3 in both healthy individuals and PNH patients (data not shown). The data presented in Table 2 LPS (ng/ml) FIG. 4. LPS-induced granulocyte Mac-1 upregulation in whole blood is defective in PNH patients. Whole blood from healthy volunteers (0) and PNH patients (0) was incubated for 2 h with medium alone or with LPS (1 to 1,000 ng/ml). Granulocytes were stained with phycoerythrin-conjugated anti-Mac-1 MAb, and fluorescence was measured by flow cytometry. Results are expressed as the change in MESF units compared with the value for granulocytes incubated with medium alone (mean + SEM for two independent experiments, each involving two different donors).
high LPS concentration (100 ng/ml), Mac-i upregulation and TNF-at production were not reduced by addition of the anti-CD14 MAb in either healthy volunteers or PNH patients, while a slight inhibition of IL-6 production was observed. In contrast, at an LPS dose of 1 ng/ml, the anti-CD14 MAb clearly inhibited the responses of normal phagocytes, confirming the major role of CD14 in this setting. Interestingly, the low phagocyte activation induced by LPS at 1 ng/ml in PNH patients was also inhibited by the addition of anti-CD14 MAb, as assessed by Mac-i expression in all three patients and by cytokine production in patient 1 (the cytokine production induced by LPS at 1 ng/ml in patients 2 and 3 was too low to quantitate the inhibition by the anti-CD14 MAb). This effect of the anti-CD14 MAb on CD14-deficient phagocytes might be related to the production of soluble sCD14 molecules by these cells (10) . Indeed, we observed the presence of sCD14 in the plasma of these 
DISCUSSION
The present study indicates that CD14-negative phagocytes from PNH patients display impaired responsiveness to LPS in a whole-blood model. First, the induction of TNF-ot production by LPS at a concentration of 1 ng/ml was markedly reduced in whole blood from PNH patients compared with that in blood from healthy volunteers, whereas at a higher dose of LPS (100 ng/ml), TNF-ao production was normal. Together with the inhibitory effect of the anti-CD14 MAb on TNF-a production elicited by a low dose of LPS in normal individuals (4, 21 ; also this study), these data support a crucial role for CD14 in LPS-induced TNF-a production. Our experiments also showed that, as for TNF-a, IL-6 production induced by LPS at 1 ng/ml is low in PNH patients but reaches normal values after stimulation with LPS at 100 ng/ml. In addition, IL-6 production in normal individuals was also inhibited by the anti-CD14 MAb, suggesting that, at low concentrations, LPS stimulates the production of both cytokines through the same receptors. Recent experiments performed with isolated cells support this hypothesis (5) .
The adhesion molecule Mac-1 plays a central role in the adhesion of both neutrophils and monocytes to vascular endothelium (12) . Upregulation of Mac-1 expression at the surface of monocytes and granulocytes can be induced in vitro on isolated cells by stimulation with LPS, TNF-a, and complement system activation product C5a (2, 14) . Our results demonstrate that, in a whole-blood model, monocyte Mac-1 upregulation by low LPS concentrations is dependent on the presence of CD14 molecules on the surface of these cells. The data obtained from studies with the patient with both normal and abnormal monocyte populations show that the defect in Mac-1 induction observed in PNH patients after stimulation with LPS at 1 ng/ml is not related to the reduced production of secondary mediators such as TNF-ot, since CD14-positive monocytes showed normal upregulation. Interestingly, granulocytes from PNH patients also display a defect in Mac-1 upregulation in response to low doses of LPS. This defect could be directly related to the lack of CD14 molecules at the granulocyte surface or could be a consequence of the decreased TNF-a production. Since the anti-CD14 blocking MAb has been shown to inhibit Mac-1 upregulation by LPS on isolated granulocytes (13) , we favor the first hypothesis.
We also observed that LPS increased ICAM-1 expression on the surface of monocytes and that this phenomenon is dependent on the presence of CD14 molecules on these cells. Monocyte ICAM-1, a ligand for the LFA-1 and Mac-1 adhesion molecules (6, 12) , has been shown to be involved, together with class II major histocompatibility complex molecules, in the presentation of antigens to T cells (1) . Thus, LPS could modulate monocyte antigen-presenting function through its binding to CD14 molecules.
Although we cannot exclude the involvement of other phosphatidylinositol-anchored proteins, our data support the concept that CD14 molecules play a major role in phagocyte responses to concentrations of LPS within the range commonly found in patients suffering from gram-negative sepsis (17) . At higher LPS concentrations, other receptors are clearly sufficient to trigger maximal release of TNF-ot and adhesion molecule upregulation. Among these receptors, the recently described 73-kDa LPS-binding molecule on the surface of human peripheral blood cells could be important (8) . As far as IL-6 is concerned, the slight inhibition induced by the anti-CD14 MAb at an LPS dose of 100 ng/ml suggests that the production of this cytokine remains partially CD14 dependent even at this high LPS concentration.
The ability of the anti-CD14 MAb to further reduce the low-grade activation of CD14-deficient phagocytes induced by LPS at 1 ng/ml could be related to the production of sCD14 molecules by these cells. Indeed, sCD14 levels in PNH patients were similar to those observed in healthy volunteers, confirming the capacity of cells from PNH patients to produce unanchored CD14 proteins (10) . sCD14 was found in other models to mediate LPS-induced activation of CD14-negative cells (7, 15) . Further investigations should clarify the role of sCD14 in phagocyte responses to LPS.
